{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:21:39Z","timestamp":1789014099450,"version":"build-2803163510"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A wide variety of new therapeutic options for Multiple Myeloma (MM) have recently become available, extending progression-free and overall survival for patients in meaningful ways. However, these treatments are not curative, and patients eventually relapse, necessitating decisions on the appropriate choice of treatment(s) for the next phase of the disease. Additionally, an important subset of MM patients will prove to be refractory to the majority of the available treatments, requiring selection of effective therapies from the remaining options. Immunomodulatory agents (IMiDs), proteasome inhibitors, monoclonal antibodies, and alkylating agents are the major classes of MM therapies, with several options in each class. Patients who are refractory to one agent in a class may be responsive to a related compound or to a drug from a different class. However, rules for selection of alternative treatments in these situations are somewhat empirical and later phase clinical trials to inform those choices are ongoing. To address these issues the NCI Multiple Myeloma Steering Committee formed a relapsed\/refractory working group to review optimal treatment choices, timing, and sequencing and provide recommendations. Additional issues considered include the role of salvage autologous stem cell transplantation, risk stratification, targeted approaches for genetic subsets of MM, appropriate clinical trial endpoints, and promising investigational agents. This report summarizes the deliberations of the working group and suggests potential avenues of research to improve the precision, timing, and durability of treatments for Myeloma.<\/jats:p>","DOI":"10.1038\/s41408-022-00695-5","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T06:09:49Z","timestamp":1656482989000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8054-6446","authenticated-orcid":false,"given":"Lawrence","family":"Baizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6975-1086","authenticated-orcid":false,"given":"Natalie S.","family":"Callander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio A.","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1778-0010","authenticated-orcid":false,"given":"Jens","family":"Hillengass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Freidlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Hoering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7426-8865","authenticated-orcid":false,"given":"Paul G.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena I.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Reiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1708-7344","authenticated-orcid":false,"given":"Suzanne","family":"Lentzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip L.","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2934-6518","authenticated-orcid":false,"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4091-1699","authenticated-orcid":false,"given":"Richard F.","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noopur S.","family":"Raje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,29]]},"reference":[{"key":"695_CR1","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/s41375-021-01453-5","volume":"36","author":"M Binder","year":"2021","unstructured":"Binder M, Nandakumar B, Rajkumar SV, Kapoor P, Buadi FK, Dingli D. Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. Leukemia. 2021;36:801. https:\/\/doi.org\/10.1038\/s41375-021-01453-5.","journal-title":"Leukemia"},{"key":"695_CR2","doi-asserted-by":"publisher","first-page":"204062072110274","DOI":"10.1177\/20406207211027463","volume":"12","author":"JP MacEwan","year":"2021","unstructured":"MacEwan JP, Majer I, Chou JW, Panjabi S. The value of survival gains from therapeutic innovations for US patients with relapsed\/refractory multiple myeloma. Ther Adv Hematol. 2021;12:20406207211027463.","journal-title":"Ther Adv Hematol"},{"key":"695_CR3","doi-asserted-by":"publisher","first-page":"3600","DOI":"10.1038\/s41375-021-01250-0","volume":"35","author":"J Corre","year":"2021","unstructured":"Corre J, Perrot A, Hulin C, Caillot D, Stoppa AM, Facon T, et al. Improved survival in multiple myeloma during the 2005\u20132009 and 2010\u20132014 periods. Leukemia. 2021;35:3600\u20133.","journal-title":"Leukemia"},{"key":"695_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08544-7","volume":"21","author":"MJ Sneyd","year":"2021","unstructured":"Sneyd MJ, Gray AR, Morison IM. Trends in survival from myeloma, 1990\u20132015: a competing risks analysis. BMC Cancer. 2021;21:821.","journal-title":"BMC Cancer"},{"key":"695_CR5","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1080\/14740338.2020.1733968","volume":"19","author":"O Nadeem","year":"2020","unstructured":"Nadeem O, Anderson KC. The safety of current and emerging therapies for multiple myeloma. Expert Opin Drug Saf. 2020;19:269\u201379.","journal-title":"Expert Opin Drug Saf"},{"key":"695_CR6","doi-asserted-by":"crossref","unstructured":"Attal M, Moreau P, Avet-Loiseau H, Harousseau JL. Stem cell transplantation in multiple myeloma. Hematology Am Soc Hematol Educ Program. 2007;311\u20136, American Society of Hematology, Washington, DC.","DOI":"10.1182\/asheducation-2007.1.311"},{"key":"695_CR7","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376:1311\u201320.","journal-title":"N Engl J Med"},{"key":"695_CR8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3324\/haematol.2015.138149","volume":"101","author":"PL McCarthy","year":"2016","unstructured":"McCarthy PL, Palumbo A, Holstein SA, Lauwers-Cances V, Petrucci MT, Richardson PG, et al. A meta-analysis of overall survival in patients with multiple myeloma treated with lenalidomide maintenance after high-dose melphalan and autologous stem cell transplant. Haematologica 2016;101:2\u20133.","journal-title":"Haematologica"},{"key":"695_CR9","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S1470-2045(20)30756-7","volume":"22","author":"P Moreau","year":"2021","unstructured":"Moreau P, Kumar SK, San Miguel J, Davies F, Zamagni E, Bahlis N, et al. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021;22:e105\u2013e18.","journal-title":"Lancet Oncol"},{"key":"695_CR10","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.6004\/jnccn.2020.0057","volume":"18","author":"SK Kumar","year":"2020","unstructured":"Kumar SK, Callander NS, Adekola K, Anderson L, Baljevic M, Campagnaro E, et al. Multiple myeloma, version 3.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2020;18:1685\u2013717.","journal-title":"J Natl Compr Canc Netw"},{"key":"695_CR11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","volume":"394","author":"P Moreau","year":"2019","unstructured":"Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet 2019;394:29\u201338.","journal-title":"Lancet"},{"key":"695_CR12","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","volume":"380","author":"T Facon","year":"2019","unstructured":"Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019;380:2104\u201315.","journal-title":"N Engl J Med"},{"key":"695_CR13","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.mayocp.2017.01.003","volume":"92","author":"D Dingli","year":"2017","unstructured":"Dingli D, Ailawadhi S, Bergsagel PL, Buadi FK, Dispenzieri A, Fonseca R, et al. Therapy for relapsed multiple myeloma: guidelines from the Mayo Stratification for Myeloma and Risk-Adapted Therapy. Mayo Clin Proc. 2017;92:578\u201398.","journal-title":"Mayo Clin Proc"},{"key":"695_CR14","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1002\/hsr2.104","volume":"2","author":"C Hulin","year":"2019","unstructured":"Hulin C, de la Rubia J, Dimopoulos MA, Terpos E, Katodritou E, Hungria V, et al. Bortezomib retreatment for relapsed and refractory multiple myeloma in real-world clinical practice. Health Sci Rep. 2019;2:e104.","journal-title":"Health Sci Rep"},{"key":"695_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/ejh.12937","volume":"100","author":"E Terpos","year":"2018","unstructured":"Terpos E, Gobbi M, Potamianou A, Lahaye M, Couturier C, Cavo M. Retreatment and prolonged therapy with subcutaneous bortezomib in patients with relapsed multiple myeloma: a randomized, controlled, phase III study. Eur J Haematol. 2018;100:10\u20139.","journal-title":"Eur J Haematol"},{"key":"695_CR16","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Spicka I, Oriol A, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372:142\u201352.","journal-title":"N Engl J Med"},{"key":"695_CR17","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374:1621\u201334.","journal-title":"N Engl J Med"},{"key":"695_CR18","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1200\/JCO.21.00972","volume":"39","author":"PG Richardson","year":"2021","unstructured":"Richardson PG, Kumar SK, Masszi T, Grzasko N, Bahlis NJ, Hansson M, et al. Final overall survival analysis of the TOURMALINE-MM1 Phase III Trial of ixazomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2021;39:2430\u201342.","journal-title":"J Clin Oncol"},{"key":"695_CR19","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373:621\u201331.","journal-title":"N Engl J Med"},{"key":"695_CR20","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","volume":"375","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:1319\u201331.","journal-title":"N Engl J Med"},{"key":"695_CR21","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","volume":"20","author":"PG Richardson","year":"2019","unstructured":"Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:781\u201394.","journal-title":"Lancet Oncol"},{"key":"695_CR22","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1038\/s41375-018-0024-1","volume":"32","author":"S Bringhen","year":"2018","unstructured":"Bringhen S, Mina R, Cafro AM, Liberati AM, Spada S, Belotti A, et al. Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed\/refractory myeloma: a phase I\/II study. Leukemia 2018;32:1803\u20137.","journal-title":"Leukemia"},{"key":"695_CR23","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1182\/blood-2015-05-643320","volume":"126","author":"JJ Shah","year":"2015","unstructured":"Shah JJ, Stadtmauer EA, Abonour R, Cohen AD, Bensinger WI, Gasparetto C, et al. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood 2015;126:2284\u201390.","journal-title":"Blood"},{"key":"695_CR24","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","volume":"396","author":"M Dimopoulos","year":"2020","unstructured":"Dimopoulos M, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet 2020;396:186\u201397.","journal-title":"Lancet"},{"key":"695_CR25","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","volume":"397","author":"P Moreau","year":"2021","unstructured":"Moreau P, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet 2021;397:2361\u201371.","journal-title":"Lancet"},{"key":"695_CR26","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","volume":"394","author":"M Attal","year":"2019","unstructured":"Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet 2019;394:2096\u2013107.","journal-title":"Lancet"},{"key":"695_CR27","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","volume":"22","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, et al. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22:801\u201312.","journal-title":"Lancet Oncol"},{"key":"695_CR28","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","volume":"21","author":"SK Kumar","year":"2020","unstructured":"Kumar SK, Harrison SJ, Cavo M, de la Rubia J, Popat R, Gasparetto C, et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 2020;21:1630\u201342.","journal-title":"Lancet Oncol"},{"key":"695_CR29","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","volume":"396","author":"S Grosicki","year":"2020","unstructured":"Grosicki S, Simonova M, Spicka I, Pour L, Kriachok I, Gavriatopoulou M, et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet 2020;396:1563\u201373.","journal-title":"Lancet"},{"key":"695_CR30","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa1714678","volume":"378","author":"MV Mateos","year":"2018","unstructured":"Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018;378:518\u201328.","journal-title":"N Engl J Med"},{"key":"695_CR31","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1182\/bloodadvances.2020003642","volume":"5","author":"PM Voorhees","year":"2021","unstructured":"Voorhees PM, Rodriguez C, Reeves B, Nathwani N, Costa LJ, Lutska Y, et al. Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN. Blood Adv. 2021;5:1092\u20136.","journal-title":"Blood Adv"},{"key":"695_CR32","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1002\/cncr.32178","volume":"125","author":"AK Nooka","year":"2019","unstructured":"Nooka AK, Joseph NS, Kaufman JL, Heffner LT, Gupta VA, Gleason C, et al. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: utility of re-treatment with daratumumab among refractory patients. Cancer 2019;125:2991\u20133000.","journal-title":"Cancer"},{"key":"695_CR33","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1038\/s41375-020-0711-6","volume":"34","author":"NJ Bahlis","year":"2020","unstructured":"Bahlis NJ, Dimopoulos MA, White DJ, Benboubker L, Cook G, Leiba M, et al. Daratumumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia. 2020;34:1875\u201384.","journal-title":"Leukemia"},{"key":"695_CR34","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.clml.2019.04.018","volume":"19","author":"RZ Orlowski","year":"2019","unstructured":"Orlowski RZ, Moreau P, Niesvizky R, Ludwig H, Oriol A, Chng WJ, et al. Carfilzomib-dexamethasone versus bortezomib-dexamethasone in relapsed or refractory multiple myeloma: updated overall survival, safety, and subgroups. Clin Lymphoma Myeloma Leuk. 2019;19:522\u201330.e1.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"695_CR35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","volume":"17","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hajek R, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17:27\u201338.","journal-title":"Lancet Oncol"},{"key":"695_CR36","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1182\/asheducation.V2014.1.255.3885263","volume":"2014","author":"PG Richardson","year":"2014","unstructured":"Richardson PG, Laubach JP, Munshi NC, Anderson KC. Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all? Hematol Am Soc Hematol Educ Program. 2014;2014:255\u201361.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"695_CR37","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1002\/cncr.26422","volume":"118","author":"SK Kumar","year":"2012","unstructured":"Kumar SK, Lacy MQ, Dispenzieri A, Buadi FK, Hayman SR, Dingli D, et al. Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma. Cancer 2012;118:1585\u201392.","journal-title":"Cancer"},{"key":"695_CR38","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1038\/s41375-020-0948-0","volume":"35","author":"H Goldschmidt","year":"2021","unstructured":"Goldschmidt H, Baertsch MA, Schlenzka J, Becker N, Habermehl C, Hielscher T, et al. Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide\/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE. Leukemia 2021;35:1134\u201344.","journal-title":"Leukemia"},{"key":"695_CR39","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1159\/000486272","volume":"139","author":"WI Gonsalves","year":"2018","unstructured":"Gonsalves WI, Kansagra A. Second autologous hematopoietic stem cell transplant as salvage therapy for relapsed multiple myeloma: a global treatment option for eligible patients. Acta Haematol. 2018;139:45\u20136.","journal-title":"Acta Haematol"},{"key":"695_CR40","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1016\/j.bbmt.2015.09.016","volume":"21","author":"S Giralt","year":"2015","unstructured":"Giralt S, Garderet L, Durie B, Cook G, Gahrton G, Bruno B, et al. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biol Blood Marrow Transpl. 2015;21:2039\u201351.","journal-title":"Biol Blood Marrow Transpl"},{"key":"695_CR41","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1182\/blood-2018-07-863829","volume":"132","author":"L Garderet","year":"2018","unstructured":"Garderet L, Kuhnowski F, Berge B, Roussel M, Escoffre-Barbe M, Lafon I, et al. Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma. Blood 2018;132:2555\u201363.","journal-title":"Blood"},{"key":"695_CR42","doi-asserted-by":"publisher","first-page":"e340","DOI":"10.1016\/S2352-3026(16)30049-7","volume":"3","author":"G Cook","year":"2016","unstructured":"Cook G, Ashcroft AJ, Cairns DA, Williams CD, Brown JM, Cavenagh JD, et al. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT\/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. Lancet Haematol. 2016;3:e340\u201351.","journal-title":"Lancet Haematol"},{"key":"695_CR43","doi-asserted-by":"crossref","unstructured":"Baertsch MA, Schlenzka J, Christina H, Hielscher T, Raab MS, Hillengass J, et al. Subgroup Analyses of the Randomized GMMG Phase III Multicenter Trial ReLApsE suggest survival benefit of salvage autologous transplant primarily in low risk multiple myeloma. Blood 2018;132:254.","DOI":"10.1182\/blood-2018-99-119762"},{"key":"695_CR44","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1016\/j.bbmt.2018.12.002","volume":"25","author":"PA Hagen","year":"2019","unstructured":"Hagen PA, Stiff P. The role of salvage second autologous hematopoietic cell transplantation in relapsed multiple myeloma. Biol Blood Marrow Transpl. 2019;25:e98\u2013e107.","journal-title":"Biol Blood Marrow Transpl"},{"key":"695_CR45","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/s41375-020-1005-8","volume":"35","author":"B Dhakal","year":"2021","unstructured":"Dhakal B, D\u2019Souza A, Kleman A, Chhabra S, Mohan M, Hari P. Salvage second transplantation in relapsed multiple myeloma. Leukemia 2021;35:1214\u20137.","journal-title":"Leukemia"},{"issue":"Suppl 2","key":"695_CR46","doi-asserted-by":"publisher","first-page":"S158","DOI":"10.1016\/S2152-2650(21)02343-0","volume":"21","author":"GBS Shah","year":"2021","unstructured":"Shah GBS, Rodriguez C, et al. Daratumumab, carfilzomib, lenalidomide, & dexamethasone for relapsed\/refractory myeloma with salvage autologous hematopoietic cell transplant: interim analysis of the multicenter 2nd chance protocol. Clin Lymphoma Myeloma Leukemia. 2021;21(Suppl 2):S158\u2013S159.","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"695_CR47","doi-asserted-by":"publisher","unstructured":"Baertsch MA, Fougereau M, Hielscher T, Sauer S, Breitkreutz I, Jordan K, et al. Carfilzomib, lenalidomide, and dexamethasone followed by salvage autologous stem cell transplant with or without maintenance for relapsed or refractory multiple myeloma. Cancers (Basel). 2021;13:4706. https:\/\/doi.org\/10.3390\/cancers13184706.","DOI":"10.3390\/cancers13184706"},{"key":"695_CR48","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1182\/blood-2015-11-682518","volume":"127","author":"RC Baz","year":"2016","unstructured":"Baz RC, Martin TG 3rd, Lin HY, Zhao X, Shain KH, Cho HJ, et al. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood 2016;127:2561\u20138.","journal-title":"Blood"},{"key":"695_CR49","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa1903455","volume":"381","author":"A Chari","year":"2019","unstructured":"Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med. 2019;381:727\u201338.","journal-title":"N Engl J Med"},{"key":"695_CR50","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40259-021-00514-6","volume":"36","author":"S Richard","year":"2022","unstructured":"Richard S, Jagannath S. Targeting nuclear export proteins in multiple myeloma therapy. BioDrugs 2022;36:13\u201325.","journal-title":"BioDrugs"},{"key":"695_CR51","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","volume":"21","author":"S Lonial","year":"2020","unstructured":"Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, Phase 2 study. Lancet Oncol. 2020;21:207\u201321.","journal-title":"Lancet Oncol"},{"key":"695_CR52","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","volume":"379","author":"MA Dimopoulos","year":"2018","unstructured":"Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med. 2018;379:1811\u201322.","journal-title":"N Engl J Med"},{"key":"695_CR53","doi-asserted-by":"publisher","unstructured":"Davis JA, Shockley A, Hashmi H. The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma. J Oncol Pharm Pract. 2022;28:960\u20138. https:\/\/doi.org\/10.1177\/10781552211073517.","DOI":"10.1177\/10781552211073517"},{"key":"695_CR54","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/ajh.26379","volume":"97","author":"A Lakshman","year":"2022","unstructured":"Lakshman A, Kumar SK. Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: an update. Am J Hematol. 2022;97:99\u2013118.","journal-title":"Am J Hematol"},{"key":"695_CR55","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr., Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705\u201316.","journal-title":"N Engl J Med"},{"key":"695_CR56","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet 2021;398:314\u201324.","journal-title":"Lancet"},{"key":"695_CR57","unstructured":"Martin TUS, Berdeja JG, Jakubowiak A, Agha M, Cohen AD, et al. Updated results from MajesTEC-1: Phase 1\/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 bispecific antibody, in relapsed\/refractory multiple myeloma. (American Society for Hematology, Washington, DC, 2021)."},{"key":"695_CR58","doi-asserted-by":"crossref","unstructured":"Moreau PUS, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel J, Oriol A, et al. Updated results from MajesTEC-1: Phase 1\/2 Study of teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in relapsed\/refractory multiple myeloma. ASH 2021 meeting abstracts; 2021.","DOI":"10.1182\/blood-2021-147915"},{"key":"695_CR59","doi-asserted-by":"publisher","unstructured":"Hosny M, Verkleij CPM, van der Schans J, Frerichs KA, Mutis T, Zweegman S, et al. Current state of the art and prospects of T cell-redirecting bispecific antibodies in multiple myeloma. J Clin Med. 2021;10:4593. https:\/\/doi.org\/10.3390\/jcm10194593.","DOI":"10.3390\/jcm10194593"},{"key":"695_CR60","doi-asserted-by":"publisher","unstructured":"Cho SF, Xing L, Anderson KC, Tai YT. Promising antigens for the new frontier of targeted immunotherapy in multiple myeloma. Cancers (Basel). 2021;13:6136. https:\/\/doi.org\/10.3390\/cancers13236136.","DOI":"10.3390\/cancers13236136"},{"key":"695_CR61","doi-asserted-by":"publisher","first-page":"3748","DOI":"10.1182\/bloodadvances.2020004146","volume":"5","author":"LJ Costa","year":"2021","unstructured":"Costa LJ, Davies FE, Monohan GP, Kovacsovics T, Burwick N, Jakubowiak A, et al. Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed\/refractory multiple myeloma. Blood Adv. 2021;5:3748\u201359.","journal-title":"Blood Adv"},{"key":"695_CR62","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1200\/JCO.21.00443","volume":"39","author":"NJ Bahlis","year":"2021","unstructured":"Bahlis NJ, Baz R, Harrison SJ, Quach H, Ho SJ, Vangsted AJ, et al. Phase I Study of venetoclax plus daratumumab and dexamethasone, with or without bortezomib, in patients with relapsed or refractory multiple myeloma with and without t(11;14). J Clin Oncol. 2021;39:3602\u201312.","journal-title":"J Clin Oncol"},{"key":"695_CR63","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","volume":"130","author":"S Kumar","year":"2017","unstructured":"Kumar S, Kaufman JL, Gasparetto C, Mikhael J, Vij R, Pegourie B, et al. Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma. Blood 2017;130:2401\u20139.","journal-title":"Blood"},{"key":"695_CR64","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/ajh.25415","volume":"94","author":"R Chakraborty","year":"2019","unstructured":"Chakraborty R, Liu HD, Rybicki L, Tomer J, Khouri J, Dean RM, et al. Progression with clinical features is associated with worse subsequent survival in multiple myeloma. Am J Hematol. 2019;94:439\u201345.","journal-title":"Am J Hematol"},{"key":"695_CR65","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.clml.2020.12.021","volume":"21","author":"AS Rosenberg","year":"2021","unstructured":"Rosenberg AS, Facon T, Parikh K, Chung W, Srinivasan S, Kotey S, et al. Association of Morbid progression with overall survival among patients with multiple myeloma: validation of the progression-free survival endpoint. Clin Lymphoma Myeloma Leuk. 2021;21:345\u201354.e4.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"695_CR66","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s00277-018-3361-2","volume":"97","author":"E Katodritou","year":"2018","unstructured":"Katodritou E, Kyrtsonis MC, Delimpasi S, Kyriakou D, Symeonidis A, Spanoudakis E, et al. Real-world data on Len\/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival. Ann Hematol. 2018;97:1671\u201382.","journal-title":"Ann Hematol"},{"key":"695_CR67","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1056\/NEJMoa1300439","volume":"369","author":"MV Mateos","year":"2013","unstructured":"Mateos MV, Hernandez MT, Giraldo P, de la Rubia J, de Arriba F, Lopez Corral L, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N. Engl J Med. 2013;369:438\u201347.","journal-title":"N. Engl J Med"},{"key":"695_CR68","doi-asserted-by":"publisher","first-page":"8001","DOI":"10.1200\/JCO.2019.37.15_suppl.8001","volume":"37","author":"S Lonial","year":"2019","unstructured":"Lonial S, Jacobus SJ, Weiss M, Kumar S, Orlowski RZ, Kaufman JL, et al. E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma. J Clin Oncol. 2019;37:8001.","journal-title":"J Clin Oncol"},{"key":"695_CR69","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/s41375-018-0271-1","volume":"33","author":"S Sidana","year":"2019","unstructured":"Sidana S, Tandon N, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, et al. Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse. Leukemia 2019;33:730\u20138.","journal-title":"Leukemia"},{"key":"695_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.13","volume":"7","author":"N Tandon","year":"2017","unstructured":"Tandon N, Rajkumar SV, LaPlant B, Pettinger A, Lacy MQ, Dispenzieri A, et al. Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma. Blood Cancer J. 2017;7:e528.","journal-title":"Blood Cancer J"},{"key":"695_CR71","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3109\/10428194.2011.627481","volume":"53","author":"V Peceliunas","year":"2012","unstructured":"Peceliunas V, Janiulioniene A, Matuzeviciene R, Zvirblis T, Griskevicius L. Circulating plasma cells predict the outcome of relapsed or refractory multiple myeloma. Leuk Lymphoma. 2012;53:641\u20137.","journal-title":"Leuk Lymphoma"},{"key":"695_CR72","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/bmt.2008.180","volume":"42","author":"S Kumar","year":"2008","unstructured":"Kumar S, Mahmood ST, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, et al. Impact of early relapse after auto-SCT for multiple myeloma. Bone Marrow Transpl. 2008;42:413\u201320.","journal-title":"Bone Marrow Transpl"},{"key":"695_CR73","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1200\/JCO.2017.76.5032","volume":"36","author":"DS Siegel","year":"2018","unstructured":"Siegel DS, Dimopoulos MA, Ludwig H, Facon T, Goldschmidt H, Jakubowiak A, et al. Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2018;36:728\u201334.","journal-title":"J Clin Oncol"},{"key":"695_CR74","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s00277-020-04384-w","volume":"100","author":"S Oliva","year":"2021","unstructured":"Oliva S, De Paoli L, Ruggeri M, Caltagirone S, Troia R, Oddolo D, et al. A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS\/SMM to newly diagnosed and relapsed multiple myeloma. Ann Hematol. 2021;100:437\u201343.","journal-title":"Ann Hematol"},{"key":"695_CR75","doi-asserted-by":"publisher","unstructured":"Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, et al. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma. J Clin Oncol. 2021;JCO2101935. https:\/\/doi.org\/10.1200\/JCO.21.01935.","DOI":"10.1200\/JCO.21.01935"},{"key":"695_CR76","doi-asserted-by":"publisher","first-page":"832645","DOI":"10.3389\/fimmu.2022.832645","volume":"13","author":"LM Alabanza","year":"2022","unstructured":"Alabanza LM, Xiong Y, Vu B, Webster B, Wu D, Hu P, et al. Armored BCMA CAR T cells eliminate multiple myeloma and are resistant to the suppressive effects of TGF-beta. Front Immunol. 2022;13:832645.","journal-title":"Front Immunol"},{"key":"695_CR77","doi-asserted-by":"publisher","first-page":"eabh1962","DOI":"10.1126\/scitranslmed.abh1962","volume":"13","author":"A Katsarou","year":"2021","unstructured":"Katsarou A, Sjostrand M, Naik J, Mansilla-Soto J, Kefala D, Kladis G, et al. Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence. Sci Transl Med. 2021;13:eabh1962.","journal-title":"Sci Transl Med"},{"key":"695_CR78","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.3109\/10428194.2010.524325","volume":"51","author":"H Chang","year":"2010","unstructured":"Chang H, Jiang A, Qi C, Trieu Y, Chen C, Reece D. Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Leuk Lymphoma. 2010;51:2084\u201391.","journal-title":"Leuk Lymphoma"},{"key":"695_CR79","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.1200\/JCO.2014.59.1503","volume":"33","author":"BA Walker","year":"2015","unstructured":"Walker BA, Boyle EM, Wardell CP, Murison A, Begum DB, Dahir NM, et al. Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J Clin Oncol. 2015;33:3911\u201320.","journal-title":"J Clin Oncol"},{"key":"695_CR80","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1038\/s41375-020-01096-y","volume":"35","author":"J Croft","year":"2021","unstructured":"Croft J, Ellis S, Sherborne AL, Sharp K, Price A, Jenner MW, et al. Copy number evolution and its relationship with patient outcome\u2014an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial. Leukemia 2021;35:2043\u201353.","journal-title":"Leukemia"},{"key":"695_CR81","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1182\/blood-2016-02-698092","volume":"128","author":"KM Kortum","year":"2016","unstructured":"Kortum KM, Mai EK, Hanafiah NH, Shi CX, Zhu YX, Bruins L, et al. Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes. Blood 2016;128:1226\u201333.","journal-title":"Blood"},{"key":"695_CR82","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","volume":"27","author":"MC Da Via","year":"2021","unstructured":"Da Via MC, Dietrich O, Truger M, Arampatzi P, Duell J, Heidemeier A, et al. Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. Nat Med. 2021;27:616\u20139.","journal-title":"Nat Med"},{"key":"695_CR83","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21177-5","volume":"12","author":"MK Samur","year":"2021","unstructured":"Samur MK, Fulciniti M, Aktas Samur A, Bazarbachi AH, Tai YT, Prabhala R, et al. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun. 2021;12:868.","journal-title":"Nat Commun"},{"key":"695_CR84","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1158\/2643-3230.BCD-20-0227","volume":"2","author":"N van de Donk","year":"2021","unstructured":"van de Donk N, Themeli M, Usmani SZ. Determinants of response and mechanisms of resistance of CAR T-cell therapy in multiple myeloma. Blood Cancer Disco. 2021;2:302\u201318.","journal-title":"Blood Cancer Disco"},{"key":"695_CR85","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1182\/blood-2011-06-297853","volume":"118","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar SV, Gahrton G, Bergsagel PL. Approach to the treatment of multiple myeloma: a clash of philosophies. Blood 2011;118:3205\u201311.","journal-title":"Blood"},{"key":"695_CR86","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","volume":"117","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 2011;117:4691\u20135.","journal-title":"Blood"},{"key":"695_CR87","doi-asserted-by":"publisher","first-page":"djv225.","DOI":"10.1093\/jnci\/djv225","volume":"107","author":"B Freidlin","year":"2015","unstructured":"Freidlin B, Little RF, Korn EL. Design issues in randomized clinical trials of maintenance therapies. J Natl Cancer Inst. 2015;107:djv225.","journal-title":"J Natl Cancer Inst"},{"key":"695_CR88","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11899-019-0495-9","volume":"14","author":"SA Holstein","year":"2019","unstructured":"Holstein SA, Suman VJ, McCarthy PL. Should overall survival remain an endpoint for multiple myeloma trials? Curr Hematol Malig Rep. 2019;14:31\u20138.","journal-title":"Curr Hematol Malig Rep"},{"key":"695_CR89","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1182\/blood-2015-05-647636","volume":"126","author":"SV Rajkumar","year":"2015","unstructured":"Rajkumar SV, Richardson P, San Miguel JF. Guidelines for determination of the number of prior lines of therapy in multiple myeloma. Blood 2015;126:921\u20132.","journal-title":"Blood"},{"key":"695_CR90","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0141-0","volume":"8","author":"PG Richardson","year":"2018","unstructured":"Richardson PG, San Miguel JF, Moreau P, Hajek R, Dimopoulos MA, Laubach JP, et al. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J. 2018;8:109.","journal-title":"Blood Cancer J"},{"key":"695_CR91","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1182\/blood.2019000406","volume":"133","author":"NR Fillmore","year":"2019","unstructured":"Fillmore NR, Yellapragada SV, Ifeorah C, Mehta A, Cirstea D, White PS, et al. With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study. Blood 2019;133:2615\u20138.","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00695-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00695-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00695-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T20:09:35Z","timestamp":1669234175000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00695-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,29]]},"references-count":91,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["695"],"URL":"https:\/\/doi.org\/10.1038\/s41408-022-00695-5","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,29]]},"assertion":[{"value":"13 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SAG receives research funding from Miltenyi Biotec, Takeda, Celgene, Amgen, Sanofi, Johnson and Johnson and Actinium and is on the advisory boards for: Kite, Celgene, Sanofi, Novartis, Johnson and Johnson, Amgen, Takeda, Jazz, and Actinium. JH reports receiving honoraria from Curio Science, Amgen, AdBoards, GSK, Axxess Network, IntelliSphere and Janssen. SJ has served as a consultant for BMS, Janssen Pharmaceuticals, Karyopharm Therapeutics, Legend Biotech, Sanofi and Takeda. SK reports research funding to Mayo from: Abbvie, Amgen, BMS, Carsgen, Janssen, Astra-Zeneca, Novartis, Roche-Genentech, Takeda, Tenebio and Molecular Templates. He has served as a consultant for Abbvie, Amgen, BMS, Janssen, Roche-Genentech, Takeda, Astra-Zeneca, Bluebird Bio, Epizyme, Secura Biotherapeutics, Monterosa therapeutics, Trillium and Oncopeptides. SL has served as a speaker for PerView, Clinical Care Options and RedMed, as a consultant for Caelum Bioscience, Pfizer, Takeda, Natara, Janssen, Celularity, Abbvie, GSK, Takeda, Karyopharm, Sanofi and Oncopetide, owns stock in Caelum Bioscience, Magenta and Poseida and has received research funding from Karyopharm and Sanofi. NSR has served as a consultant for BMS, Janssen, Pfizer, Amgen. Takeda, Abbvie and Sanofi, on the scientific advisory board for Caribou Bioscience and Immuneel and has received research funding from Bluebird Bio. PGR has received payments\/honoraria from Oncopeptides, Celgene\/BMS, Takeda, Karyopharm, Janssen, Sanofi, Secura Bio, GSK, Regeneron, AstraZeneca and Protocol Intelligence and reports interests in Oncopeptides, Celgene\/BMS, Takeda and Karyopharm. AJY has served as a consultant for Adaptive, Amgen, BMS, Celgene, GSK, Janssen, Karyopharm, Oncopeptides, Regeneron, Sanofi, and Takeda. LB, NSC, BF, AH, RFL, PLM, AR, and EIS declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"98"}}